| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Pharmacology & Pharmacy |
| Manuscript Type |
Basic Study |
| Article Title |
Naringenin prevents experimental liver fibrosis by blocking TGFβ-Smad3 and JNK-Smad3 pathways
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Erika Hernández-Aquino, Natanael Zarco, Sael Casas-Grajales, Erika Ramos-Tovar, Rosa E Flores-Beltrán, Jonathan Arauz, Mineko Shibayama, Liliana Favari, Víctor Tsutsumi, José Segovia and Pablo Muriel |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Council of Science and Technology (Conacyt) of Mexico |
253037 |
| National Council of Science and Technology (Conacyt) of Mexico |
239516 |
| Fellowship from Conacyt |
358378 |
|
| Corresponding Author |
Pablo Muriel, PhD, Laboratory of Experimental Hepatology, Department of Pharmacology, CINVESTAV-IPN, Av. Instituto Politécnico Nacional 2508, Apartado Postal 14–740, 07000, Mexico City, Mexico. pmuriel@cinvestav.mx |
| Key Words |
Fibrosis; Transforming growth factor-β; Naringenin; pSmad3; Smad3; JNK; Nuclear factor kappa; Carbon tetrachloride |
| Core Tip |
To study the effect of naringenin (NAR) on carbon tetrachloride (CCl4)-induced chronic liver fibrosis, male Wistar rats were administered 400 mg of CCl4/kg body weight and 100 mg of NAR/kg body weight for 8 wk. NAR prevented necrosis, cholestasis, oxidative stress, collagen accumulation and the increase in MMP activity caused by CCl4 administration. NAR completely prevented the increase in TGF-β, α-SMA, CTGF, Col-1, MMP-13, NF-κB, IL-1 and IL-10 protein levels caused by CCl4 administration and pSmad3 and pJNK activation. In conclusion, NAR prevents CCl4 induced liver fibrosis due to its antioxidant capacity and by inhibiting the TGF-β-Smad3, JNK-Smad3 and NF-κB pathways. |
| Publish Date |
2017-06-26 10:23 |
| Citation |
Hernández-Aquino E, Zarco N, Casas-Grajales S, Ramos-Tovar E, Flores-Beltrán RE, Arauz J, Shibayama M, Favari L, Tsutsumi V, Segovia J, Muriel P. Naringenin prevents experimental liver fibrosis by blocking TGFβ-Smad3 and JNK-Smad3 pathways. World J Gastroenterol 2017; 23(24): 4354-4368 |
| URL |
http://www.wjgnet.com/1007-9327/full/v23/i24/4354.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v23.i24.4354 |
